Pfizer offers Ibrance free to the NHS during NICE appraisal
Pfizer is to offer its breast cancer drug Ibrance free to the NHS while cost regulators decide whether it should be routinely funded in England and Wales.
Read More
Tag: patient programme
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
